Corporate information
Official name
Aderis Pharmaceuticals Incorporated
Registration country
Company type
Novel small molecule, receptor-specific therapeutics company for the treatment of central nervous system, cardiovascular and renal diseases.Funding rounds
Series D USD 45,000,000
USD 45,000,000 ( )
Investor | Profile | Country | Notes | |
---|---|---|---|---|
Paladin Capital Group | Private equity firm | Initial investment. Led the round. | ||
China Development Industrial Bank (CDIB) | Private development financial institution in Taiwan. | Initial investment. | ||
International Biotechnology Trust PLC | Initial investment. | |||
MDS Capital Corp | Initial investment. | |||
NeoMed Management AS | Initial investment. | |||
Perseus-Soros BioPharmaceutical Fund LP | Initial investment. | |||
Sanderling Ventures | Initial investment. | |||
Schroder Ventures KK | Initial investment. | |||
Singapore Bio-Innovations | Initial investment. | |||
Temasek Holdings (Pte) Ltd | Singapore's sovereign wealth fund. | Initial investment. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
Lumira Capital Investment Management Inc (Lumira Ventures) | Canadian healthcare and life sciences venture capital firm. | Initial investment. |
Investment activity status
Active investor